Simdax (levosimendan IV) / AbbVie, Orion Corp, Tenax Therap - LARVOL DELTA

Classifying Sickle Cell Disease Subtypes from Clinical Reports: Algorithm Validation and ICD-10 Accuracy Assessment in Five French Hospitals. (PubMed, J Med Syst) - "This simple algorithm effectively classifies SCD subtypes and SCT from clinical reports. Despite the large multicenter sample, performance may reflect the specific subtype demographics, expertise, and documentation practices of the study setting. This work highlights the risk of misclassification when relying solely on ICD-10 coding and the importance of high-quality clinical documentation for retrospective research."

Journal • Genetic Disorders • Hematological Disorders • Rare Diseases • Sickle Cell Disease

Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal Function (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: Ain Shams University | Phase classification: P ➔ P4

Phase classification • Cardiovascular • Congestive Heart Failure • Heart Failure • Nephrology

Levosimendan for Weaning From Veno-Arterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock: An Umbrella Review. (PubMed, Cureus) - "AMSTAR 2 confidence ratings ranged from low (n=2) to moderate (n=4) to high (n=1), substantial primary-study overlap was identified across reviews, and GRADE certainty, where formally assessed, was rated very low. Levosimendan may be associated with improved VA-ECMO weaning success and a possible mortality benefit in CS, particularly in patients with combined cardiac insufficiency, but this concordance rests on overlapping, retrospective, non-randomized cohorts, making it hypothesis-generating rather than an evidence-based standard pending adequately powered randomized controlled trials."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Myocardial Rest in Cardiogenic Shock: Lessons from LEVOECMO and Contemporary Trials. (PubMed, ESC Heart Fail) - No abstract available

Journal • Cardiovascular

Update on Perioperative Prevention of Cardiac Surgery-Associated Acute Kidney Injury. (PubMed, J Clin Med) - "Remote ischemic preconditioning, pulsatile flow, minimally invasive extracorporeal circulation, dexmedetomidine, N-acetylcysteine, levosimendan, hemoadsorption with the oXiris membrane, and natriuretic peptides show variable or subgroup-dependent signals limited by heterogeneous trial design and acute kidney injury (AKI) definitions. Prevention of CS-AKI is, therefore, best conceived as a multimodal, patient-centered process integrating preoperative risk stratification, intraoperative oxygen delivery optimization, patient blood management (PBM), and postoperative nephrotoxin avoidance and surveillance."

Journal • Review • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Inflammation • Nephrology • Renal Disease • Reperfusion Injury

Acute hemodynamic and echocardiographic responses to pimobendan versus levosimendan in a dog with decompensated dilated cardiomyopathy. (PubMed, Vet Res Commun) - "These findings represent descriptive clinical observations from the management of a single patient and should not be interpreted as evidence of comparative efficacy or superiority of one inodilator over another. Because atrial fibrillation and temporal variation in heart rate may have influenced echocardiographic measurements throughout the monitoring period, the findings should be interpreted within the methodological limitations of this sequential single-case report."

Journal • Acute Respiratory Distress Syndrome • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Levosimendan Enhances Weaning Success And Survival In Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) Patients: A Comprehensive Meta-analysis Of Randomized Trials And Observational Studies [Poster no. 644] (HFSA 2026) - No abstract available

Observational data • Retrospective data

Levosimendan versus Dobutamine in Hospitalized Heart Failure With and Without Beta-Blocker Therapy: A Multinational Propensity-Matched Real-World Analysis (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure

Levosimendan as an Adjunct During Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) for Cardiogenic Shock: A Systematic Review and Meta-Analysis (AHA 2026) - "Abstract is embargoed at this time."

Retrospective data • Review • Cardiovascular

Multimodal Monitoring in Eclamptic Intracerebral Hemorrhage Complicated by Reversible Cerebral Vasoconstriction Syndrome (RCVS): A Case Report. (PubMed, Case Rep Crit Care) - "Treatment with verapamil and levosimendan resulted in rapid normalization of Doppler velocities without systemic hypotension. This case underscores the value of bedside TCCD integrated with multimodal neuromonitoring in the management of a complicated eclampsia with ICH and RCVS. Assessment of cerebral hemodynamics and perfusion may support safe conservative management in high-risk neuro-intensive care patients."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Critical care • Epilepsy • Hematological Disorders • Hypertension • Hypotension • Obstetrics

LEVOSAH: Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage (clinicaltrials.gov) - P2 | N=30 | Completed | Sponsor: Assistance Publique - Hpitaux de Paris | Recruiting ➔ Completed

Trial completion • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage

Impact of levosimendan versus dobutamine on 30-day mortality and hospital stay in acute decompensated heart failure: a systematic review and meta-analysis (ESC 2026) - "Conclusion In adults with ADHF and low cardiac output, levosimendan was associated with lower short-term mortality and shorter hospital stay compared with dobutamine, with signals of renal benefit. Larger contemporary trials are needed to confirm these findings and to define the optimal use of levosimendan in this high-risk population."

Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Levosimendan administration and survival in patients receiving mechanical circulatory support: insights from an unselected real-world cohort (ESC 2026) - "While norepinephrine, epinephrine, and dobutamine represent standard treatment, the prognostic relevance of levosimendan administration in this setting remains uncertain. In this retrospective real-world MCS cohort, levosimendan administration was independently associated with reduced short-term mortality and improved long-term survival, including in resuscitated patients. While residual confounding inherent to the observational design cannot be excluded, these findings support prospective evaluation of levosimendan as adjunctive therapy in advanced cardiogenic shock."

Clinical • Real-world • Real-world evidence • Cardiovascular

Levosimendan in patients with pulmonary hypertension due to heart failure with preserved ejection fraction: results of the LEVEL trial (ESC 2026) - No abstract available

Clinical • Late-breaking abstract • Cardiovascular • Congestive Heart Failure • Heart Failure

Levosimendan in heart transplantation: a systemic review and meta-analysis (ESC 2026) - "Overall, LEVO use was generally well-tolerated in terms of adverse effects, with no consistent signal for increased risk of arrhythmias, symptomatic hypotension, or renal impairment.ConclusionLEVO use in the HTx setting was associated with a higher mortality rate in bridge-to-transplant patients, a longer requirement of ECMO support, and a higher short-term mortality in PGD/F. These findings do not support the routine use of LEVO in this population and highlight the need for robust prospective studies."

Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension

Blueprint for a nurse-led heart failure day hospital in mexico: implementation science and pedagogical insights from a 7-year interinstitutional training collaboration (ESC 2026) - "Key deliverables: co-designed clinical protocols (patient selection, infusion algorithms for furosemide, levosimendan, IV iron), adverse event pathways, and nurse-led follow-up. This blueprint provides an evidence-based model for a nurse-led HF day hospital in a resource-limited public setting, grounded in 7 years of interinstitutional experience and a robust pedagogical framework. Identified barriers offer authentic insights for global implementation science, positioning the unit for a Spring 2026 opening and offering a scalable model for similar initiatives worldwide."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Mixed cardiogenic–vasodilatory phenotypes in cardiogenic shock: insights from real-world advanced hemodynamic monitoring (ESC 2026) - "CS patients received more restrictive fluids and more frequent mechanical circulatory support, while septic shock patients underwent larger early resuscitation followed by de‑resuscitation (Figure B); norepinephrine was the dominant vasopressor in both entities, with vasopressin mainly used in sepsis and inotropes (dobutamine, levosimendan) in CS. Although AHM refines cardiovascular phenotyping and may support escalation strategies including MCS, single hemodynamic parameters are not prognostic. These findings support a trajectory-based cardiovascular approach to CS rather than static shock categorization."

Clinical • Metastases • Real-world • Real-world evidence • Cardiovascular

LAKIS: Levosimendan in Acute Kidney Injury Study (clinicaltrials.gov) - P2/3 | N=68 | Completed | Sponsor: VieCuri Medical Centre | Unknown status ➔ Completed

Trial completion • Acute Kidney Injury • Critical care • Nephrology • Renal Disease

Optimization of levosimendan before left ventricular assist device implantation in pediatric patients. (PubMed, Int J Artif Organs) - "Preoperative levosimendan administration seems to be safe in pediatric LVAD candidates and is associated with improved end-organ function, although it has not demonstrated superiority over standard inotropic therapy in terms of preventing right ventricular failure or reducing mortality."

Journal • Cardiovascular • Hypotension • Pediatrics

Factors Associated with Progression to SCAI-Defined Hemodynamic Instability at 72 Hours in Patients with Acute Decompensated Heart Failure Receiving Inotropic Therapy. (PubMed, J Clin Med) - " This retrospective, single-center study included 375 adults with ADHF who received intravenous dobutamine or levosimendan and were classified as SCAI stage A or B at the time of inotrope initiation. In bootstrap analysis, the association remained significant for WBC, whereas the association with DBP was borderline. Higher WBC and lower DBP were associated with progression to SCAI stage C-E at 72 h in this exploratory single-center cohort of patients with ADHF receiving inotropic therapy."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • CRP

Levosimendan During VA-ECMO for Cardiogenic Shock: An Updated Systematic Review and Meta-analysis Including the LEVOECMO Trial. (PubMed, J Cardiothorac Vasc Anesth) - "The apparent weaning benefit of levosimendan was driven mainly by nonrandomized evidence and was not confirmed by the LEVOECMO randomized trial. No reduction in 28- and/or 30-day mortality was observed, and current evidence does not support routine levosimendan use during VA-ECMO."

Journal • Retrospective data • Review • Cardiovascular

Levosimendan in Severe Renal Insufficiency: Efficacy and Safety from a Systematic Review and Meta-Analysis. (PubMed, Curr Cardiol Rev) - "This study found that available evidence from small, heterogeneous observational studies is insufficient to determine whether levosimendan affects mortality in severe renal insufficiency. These findings do not support any clinical recommendation, provide no basis to modify the existing contraindication for Ccr below 30 mL/min, and highlight the need for further RCTs with comprehensive endpoints."

Clinical • Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease

Inhaled pulmonary vasodilators in pulmonary hypertension: Perioperative use and clinical considerations. (PubMed, JHLT Open) - "Traditional vasodilators such as nitroglycerin and sodium nitroprusside lack pulmonary specificity and can exacerbate systemic hypotension. Inhaled agents including nitric oxide (NO), epoprostenol (iEPO), iloprost, milrinone (iMIL) and levosimendan provide selective pulmonary vasodilation with more favorable hemodynamic profiles...Overall, iPVs represent a valuable tool in the perioperative care of patients with PH. Continued research is needed to refine clinical protocols, evaluate emerging agents, and establish outcome-based evidence for their routine use."

Journal • Anesthesia • Cardiovascular • Hypertension • Hypotension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Levosimendan for Weaning from VA-ECMO: Two Trials, Two Timings. (PubMed, J Cardiothorac Vasc Anesth) - No abstract available

Journal

Repurposed cAMP-Modulating Agents Enhance 5-Fluorouracil Response Through Membrane-Dependent Mechanisms. (PubMed, Membranes (Basel)) - "Here, we propose a membrane-centered framework in which compartmentalized cAMP/PKA signaling, modulated by repurposed vasoregulatory agents-levosimendan, milrinone, and terbutaline-enhances 5-FU response by functionally remodeling the cancer cell membrane. Clinical translation requires rigorous pharmacokinetic-pharmacodynamic validation and cardiovascular safety assessment. Redefining the plasma membrane as a dynamic therapeutic interface may provide a rationale for drug repurposing, patient stratification, and personalized combination strategies."

Journal • Review • Bladder Cancer • Cardiovascular • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • SLC29A1 • TYMS